MLAB vs RGEN

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus 11. 5% for Mesa Laboratories, Inc. (MLAB). Repligen Corporation (RGEN) offers the better valuation at 147. 0x trailing P/E (64. 3x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Mesa Laboratories, Inc.

is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Repligen Corporation (RGEN) delivered a total return of -32.

7%, compared to -56. 5% for Mesa Laboratories, Inc. (MLAB). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus MLAB's +4. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Repligen Corporation (RGEN) is the lower-risk stock at 1.

76β versus Mesa Laboratories, Inc. 's 1. 78β — meaning MLAB is approximately 2% more volatile than RGEN relative to the S&P 500. On balance sheet safety, Repligen Corporation (RGEN) carries a lower debt/equity ratio of 33% versus 114% for Mesa Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus 11. 5% for Mesa Laboratories, Inc. (MLAB). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to 99. 2% for Mesa Laboratories, Inc.. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Repligen Corporation (RGEN) is the more profitable company, earning 6.

6% net margin versus -0. 8% for Mesa Laboratories, Inc. — meaning it keeps 6. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGEN leads at 8. 1% versus 6. 8% for MLAB. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Mesa Laboratories, Inc.

(MLAB) trades at 11. 7x forward P/E versus 64. 3x for Repligen Corporation — 52. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGEN: 32. 9% to $168. 00.

In this comparison, MLAB (0.

6% yield) pays a dividend. RGEN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mesa Laboratories, Inc.

(MLAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 6% yield). Repligen Corporation (RGEN) carries a higher beta of 1. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLAB: +4. 5%, RGEN: +369. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MLAB (Technology) and RGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MLAB is a small-cap quality compounder stock; RGEN is a small-cap high-growth stock. MLAB pays a dividend while RGEN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.